Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users
- 25 July 2014
- journal article
- research article
- Published by Wiley in Addiction Biology
- Vol. 20 (4) , 784-798
Abstract
In spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone. However, clinical research has not yet examined the utility of the combined formulation to deter intranasal use in a buprenorphine‐maintained population. Heroin‐using volunteers (n = 12) lived in the hospital for 8–9 weeks and were maintained on each of three sublingual buprenorphine doses (2, 8, 24 mg). Under each maintenance dose, participants completed laboratory sessions during which the reinforcing and subjective effects of intranasal doses of buprenorphine (8, 16 mg), buprenorphine/naloxone (8/2, 8/8, 8/16, 16/4 mg) and controls (placebo, heroin 100 mg, naloxone 4 mg) were assessed. Intranasal buprenorphine alone typically produced increases in positive subjective effects and the 8 mg dose was self‐administered above the level of placebo. The addition of naloxone dose dependently reduced positive subjective effects and increased aversive effects. No buprenorphine/naloxone combination dose was self‐administered significantly more than placebo. These data suggest that within a buprenorphine‐dependent population, intranasal buprenorphine/naloxone has reduced abuse potential in comparison to buprenorphine alone. These data strongly argue in favor of buprenorphine/naloxone rather than buprenorphine alone as the more reasonable option for managing the risk of buprenorphine misuse.Keywords
Funding Information
- Reckitt-Benckiser Pharmaceuticals
- National Institute on Drug Abuse (K01DA030446)
This publication has 56 references indexed in Scilit:
- The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusersAddiction, 2011
- The Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Patients with Chronic, Non-Malignant Pain who are Maintained on Sublingual Buprenorphine/NaloxoneNeuropsychopharmacology, 2010
- Route of administration for illicit prescription opioids: a comparison of rural and urban drug usersHarm Reduction Journal, 2010
- Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusersPsychopharmacology, 2010
- Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusersAddiction, 2010
- Indicators of Buprenorphine and Methadone Use and Abuse: What Do We Know?The American Journal on Addictions, 2009
- Concurrent buprenorphine and benzodiazepines use and self‐reported opioid toxicity in opioid substitution treatmentAddiction, 2007
- French Field Experience with BuprenorphineThe American Journal on Addictions, 2004
- Self-Administration of Intravenous Buprenorphine and the Buprenorphine/Naloxone Combination by Recently Detoxified Heroin AbusersThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Effects of sublingually given naloxone in opioid-dependent human volunteersDrug and Alcohol Dependence, 1990